Significantly more patients met the threshold of 30 % or greater with milnacipran ( 100 mg/d , 17.6 % ; 200 mg/d , 15.2 % ) than with placebo ( 9.9 % ) ; odds ratios for this responder status were 1.93 and 1.63 , respectively ( P < 0.05 for both doses ) .